First Tracks Biotherapeutics, Inc.

United States

Last price 45.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.89B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). Fir...